Companion Diagnostics (CDx) provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases. For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs. PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology. Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.
